Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
98.05
+2.15 (2.24%)
Sep 30, 2026, 4:08 PM HKT

Innovent Biologics Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
15,70613,0429,4226,2064,5564,270
Revenue Growth
20.43%38.42%51.82%36.21%6.71%11.08%
Gross Profit
12,0179,9987,1634,3993,1753,045
Operating Income
1,166733.62-123.3-1,564-3,123-2,703
Net Income
1,232813.57-94.63-1,028-2,179-2,729
Earnings Per Share
0.700.47-0.06-0.66-1.46-1.88
EPS Growth
48.06%-----

Revenue by Geography

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
The People's Republic of China (PRC)
15,10412,0698,9835,7534,1333,968
United States of America ("USA")
343.31380.61411.59442.6411.03261.64
Europe
20.46571.81----
Other
-19.6326.8810.1212.81-
Total
15,70613,0429,4226,2064,5564,270

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
20,00318,2317,88410,9709,1669,015
Total Debt
2,3232,8162,8313,6213,2292,497
Net Cash (Debt)
17,68015,4165,0537,3495,9386,518
Net Cash Growth
14.69%205.10%-31.25%23.77%-8.91%-5.73%
Net Cash Per Share
9.858.853.104.713.984.48

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
13,27610,0011,287147.81-1,919-2,025
Capital Expenditures
-339.38-269.88-965.67-1,119-896.9-1,066
Free Cash Flow
12,9369,731321.36-971.58-2,816-3,090
Free Cash Flow Growth
32.94%2928.12%----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
76.51%76.66%76.03%70.89%69.67%71.32%
Operating Margin
7.42%5.63%-1.31%-25.20%-68.54%-63.31%
Pretax Margin
9.89%6.43%-0.83%-18.44%-47.64%-61.87%
Profit Margin
7.85%6.24%-1.00%-16.56%-47.83%-63.91%
FCF Margin
82.36%74.62%3.41%-15.65%-61.80%-72.38%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
122.05146.09----
Forward PE
46.9042.67----
P/FCF Ratio
11.4312.21175.32---
PS Ratio
9.419.115.9810.149.9813.46